drugset / Trial / NCT04970901
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.
Timeline
- Start
- 2022-06-17
- Primary completion
- 2027-03-31
- Completion
- 2028-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glofitamab | Monoclonal antibody | 30 mg | Intravenous |
| Subject | Loncastuximab Tesirine | Other / unclassified | 90 ug/kg | Intravenous |
| Subject | Loncastuximab Tesirine | Other / unclassified | 150 ug/kg | Intravenous |
| Subject | Mosunetuzumab | Monoclonal antibody | 45 mg | Subcutaneous |
| Subject | Polatuzumab Vedotin | Other / unclassified | 1.8 mg/kg | Intravenous |
| Background | Obinutuzumab | Monoclonal antibody | 1000 mg | Intravenous |